CTOs on the Move

TG Therapeutics

www.tgtherapeutics.com

 
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

TG Therapeutics raised $50M on 12/24/2019

Similar Companies

Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression. Our integrated epigenetics platform enables us to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. We are able to target a broad variety of epigenetic regulators using our platform and have generated development candidates acting against distinct classes of those regulators.

Timtec

Timtec is a Newark, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arisaph Pharmaceuticals

Arisaph Pharmaceuticals is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aruvant

Aruvant`s mission is to bring hope to patients living with rare diseases by developing life changing and potentially curative gene therapies, with a near-term focus on sickle cell disease. Aruvant is a part of the Roivant family of companies. We have a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. We have an active research program with a lead product candidate in development for individuals suffering from sickle cell disease (SCD). Our lead product candidate, ARU-1801, an investigational lentiviral gene therapy, is currently in a clinical trial as a potential one-time curative treatment for SCD. Preliminary clinical data from the ongoing Phase 1/2 study demonstrated durable efficacy in reducing the negative impacts of SCD. We are preparing for the launch of our pivotal clinical trial in SCD. We continue to look for new people to add to our talented team.

Mesa Biotech

Accurate. Accessible. Actionable. Simplifying PCR, transforming healthcare.